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aAortic Stenosis
A. National Heart, Lung, and Blood Institute: review
and agenda for research (1).
B. Left ventricular mid-wall fibrosis is significantly re-
lated to mortality in patients with aortic stenosis. A total
of 143 patients, 68  14 years of age who underwent
cardiovascular magnetic resonance with administration of
gadolinium contrast were enrolled into a study; 67.8% were
males. Late gadolinium enhancement (LGE) was assessed
by independent blinded observers who categorized the
patients into 3 subgroups: no LGE (n  49), mid-wall
MW) LGE (n  54), and infarct LGE (n  40) (2).
istological confirmation of fibrosis in the region of LGE
as obtained from biopsy specimens obtained at the time of
urgical aortic valve replacement (SAVR). Aortic valve
eplacement (AVR) was performed in 55% of those with no
GE, in 46% who had MW-LGE, and 53% who had
nfarct LGE. Follow-up was for 2.0  1.4 years. Both
all-cause mortality and cardiac-cause mortality were greater
in those with infarct LGE and MW-LGE than in those
with no LGE, and there was no significant difference
between infarct LGE and MW-LGE. On multivariate
analysis, left ventricular (LV) ejection fraction (LVEF)
(hazard ratio [HR]: 0.96; 95% confidence interval [CI]:
0.94 to 0.99; p  0.009) and MW-LGE (HR: 5.35; 95%
CI: 1.16 to 24.56; p  0.0034) were identified as indepen-
ent predictors of subsequent all-cause mortality.
omment: This is an important study. The accompanying
ditorial is excellent (3). Both the paper and the editorial
rovide a lucid and scholarly discussion of the possibilities of
tiology and cause(s) of death of MW-LGE. Although the
tiology and the mechanism of fibrosis in MW-LGE are
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ated in such patients. However, their prognosis is wors-
ned; even with a 1% increase in the percentage of LGE
ass, the overall mortality was increased by 5% (HR: 1.05;
5% CI: 1.01 to 1.09; p  0.005) (3).
. Patients with severe aortic stenosis and diabetes
ellitus have worsened LV diastolic dysfunction. Pa-
ients with severe aortic stenosis (AS) who were referred
or AVR were divided into those without diabetes mel-
itus (DM) (AS; n  46) and those with DM (AS-DM;
 16) (4).
AS-DM patients had reduced LV distensibility as evi-
enced by higher LV end-diastolic pressure (28  4 mm Hg
s. 21  1 mm Hg; p  0.04) at comparable LV end-
iastolic volumes. This was attributed to higher myocardial
ollagen volume fraction (18.2 2.6% vs. 12.9 1.1%; p
.001); more advanced glycation end-product deposition in
rterioles, venules, and capillaries; and higher resting myo-
ardial tension (Fpassive), which was related to hypophos-
phorylation of the N2B titin isoform.
Comment: Patients with DM have a higher rate of struc-
tural valve deterioration (SVD) of bioprosthesis (see the
following text). Those with LV diastolic dysfunction have a
higher rate of postoperative atrial fibrillation after cardiac
surgery of CABG valve and multivalvular procedures (see
he following).
. Excellent results of SAVR in patients 80 years of age
nd older. A meta-analysis of 48 studies in 13,216 patients
valuated hospital mortality (Table 1) and survival up to 10
ears (5). The incidence of stroke was 2.4% (95% CI: 2.1%
o 2.7%), of postoperative dialysis, it was 2.6% (95% CI:
.6% to 3.8%), and of postoperative pacemaker implanta-
ion, it was 4.6% (95% CI: 3.6% to 5.8%). Survival at 1 year
as 87.6% (95% CI: 86.0 to 89.1, data from 28 studies
ncluding 3,883 at-risk patients); at 5 years, survival was
5.4% (95% CI: 68.5% to 69.1%, data from 22 studies
ncluding at-risk 2,415 patients); and at 10 years, survival
as 29.7% (95% CI: 22.1% to 37.9%, data from 10 studies
ncluding 867 at-risk patients) (Fig. 1).
A single-center study from Rennes, France, reported on
,193 consecutive patients 82.5  2.3 years of age and older
range, 80 to 96 years) who underwent AVR between 2000
nd 2009. The hospital mortality rate was 6.9%; for single
VR, it was 5.5% and for AVR  coronary artery bypass
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operative morality were identified (6).
Comment: These are important and valuable studies.
E. SAVR for severe AS in patients with cancer is
associated with improved survival. At the University of
Texas MD Anderson Cancer Hospital, 39,071 echocardio-
grams were obtained between January 2001 and April 2007
(7); 1,299 demonstrated AS (3.3%). In 50 patients, AS was
severe, and 2 patients who had balloon valvuloplasty were
excluded. The age of the remaining 48 patients was 69.43
10.35 years; 60% had symptoms of severe AS. There were
multiple cancer types, and a special classification that was
previously described and found useful was used; 75% of the
patients had advanced cancer and 32% had metastases. All
patients were treated for cancer; 13 of 48 (27%) patients
who underwent AVR had better survival (p  0.0006) than
those treated medically for AS (Fig. 2). Patients who
underwent AVR had a better survival rate than those treated
with medical therapy, even in those with advanced cancer
and those with metastases. Cancer status was not found to
influence overall status in patients treated for AS. Note:
Patients who underwent AVR were selected by physicians
specializing in the care of the complex cancer patient and
using a multidisciplinary approach.
SAVR for Octogenarians: Meta-analysis Pooled DataTable 1 SAVR for Octogenarians: Meta-analysis Pooled Data
No. of
Studies
No. of
Patients
Hospital
Mortality, % 95% (CI)
Total
1982–2006 47 13,092 6.7 5.8–7.5
1982–1999 30 — 7.5 6.8–8.2
2000–2006 18 — 5.8 4.8–6.9
SAVR
Primary isolated 4 841 4.6 3.3–6.1
Plus previous surgery 8 1,981 6.6 5.0–8.3
EUROSCORE 15%* 4 — 6.1 3.5–10.5
*Average: range, 11.9 to 18.0.
CI confidence interval; SAVR surgical aortic valve replacement. Reprinted, with permission,
from Vasques (5).
Figure 1 Late Survival After Isolated AVR in Patients 80 Years
Of 48 studies with 13,216 patients, survival data at 1 year were available in 28 studi
replacement (AVR) are listed at the bottom of the figure. Survival rate at 1, 5, and 10Comment: This is an important study even though the
number of patients with severe AS was small.
F. Pulmonary hypertension in patients with severe AS:
better survival with SAVR. Data are presented for 317
patients with severe AS (aortic valve area 1.0 cm2) who
nderwent right and left heart catheterization between 2004
nd 2009 (8). Of 317 patients (25.6%), 81 had severe
ulmonary hypertension (PHTN) (mean pulmonary artery
PA) pressure 35 mm Hg); 35 who underwent SAVR
ere compared with 46 who did not undergo AVR. In those
ith severe PHTN, the 30-day mortality rate in those who
nderwent AVR was 2.85% versus 10.86% in patients who
id not undergo AVR (p  0.001). At follow-up (339.0 
343.7 days), the mortality rate in those who underwent
AVR versus those who did not was 14.2% versus 50% (p 
0.001; 114 of 317 [36%] had mild-moderate PHTN).
Among patients with mild-moderate and severe PHTN
who underwent AVR, the operative and long-term mortal-
ity rates were similar. Associated mitral valve replacement
(MVR) was higher in the severe subgroup than in the mild
to moderate subgroup (22.4% vs. 11.4%, p  0.032).
Comment: This is an interesting study. The general thrust
of their findings and conclusions, including their statement
that right heart catheterization “. . .is the gold standard for
the diagnosis of PH” (PHTN) is appropriate. However, 3
issues raise concerns. 1) In their patients who had severe
PHTN, the operative mortality rate of SAVR was very low
(2.85%), indicating excellent surgical results. Should the
enthusiasm for SAVR be more strongly endorsed? 2) The
reasons for MVR in 33% of patients were not provided.
3) In 2 studies of normal subjects, the values for the mean
PA (mean  2 SD) were 17  6 and 17  1.4 mm Hg,
respectively (9,10). The mean PA of 25 mm Hg is
considered to indicate PHTN by the pulmonary arterial
hypertension group (11,12). In the present study, the mean
PA SD in the mild-moderate group was 22.5 6.6 mmHg
and in the severe group was 45.3  8.3 mm Hg, and, thus,
e and Older
3,863 patients at risk. Patient survival rates at 1 to 10 years after aortic valve
was 87.6%, 65.4%, and 29.7%. Reprinted, with permission, from Vasques et al (5).of Ag
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moderate or greater PHTN, respectively.
G. Is valvular arterial impedance LV global afterload in
AS? For 52 asymptomatic patients, 72  11 years of age,
with severe AS (aortic valve area index 0.6 cm2/m2) and
LVEF 0.50, global LV afterload was determined by
measuring valvular arterial impedance (Zva) by echocardi-
graphy and were followed clinically (13). The event rate
etermined from this measurement was 55% at 12
onths. There were 2 deaths and 2 patients had heart failure
HF); AVR was required for symptoms in 26 patients within
 2months. Follow-up information was available for only 38
atients (73%); symptoms led to the event in 26 of 38 patients
70%). Predictors of events were global longitudinal strain and
va 4.7 mm Hg/ml/m
2.
omment: The classic experimental and clinical studies of
raunwald et al. (14) in the 1960s based on muscle mechanics
ere included in a monograph that stated that LV afterload is
he load that the LV has to overcome to empty and is “defined
s the tension developed in the wall of the ventricle.” It is
easured from LV pressure, volume, and mass integrated
hroughout systolic contraction (14). Is Zva LV afterload in AS?
The formula for Zva (15) is systolic blood pressure by cuffmean
V gradient by Doppler echocardiography/stroke volume index,
hich, in elementary mathematics, is (systolic blood pressure 
ean AV gradient/stroke volume) body surface area. It resem-
les vascular resistance (pressure flow), which was then multi-
lied by body surface area. Neither the cuff systolic blood pressure
or stroke volume is indicative of LV pressure and volume
hroughout systole. Zva has not been demonstrated to have any
physiological basis and in AS should not be referred to as “global
Figure 2 Survival in Patients With
Severe Aortic Stenosis and Cancer
Kaplan-Meier analysis shows survival after aortic valve replacement (AVR) (red) is
significantly better than with medical therapy (blue) for aortic stenosis.
Both groups were also treated for cancer. Reprinted, with permission, from
Yusuf et al. (7).afterload or LV afterload or valvular arterial impedance.”The present study adds to other earlier retrospective
studies showing that Zva is useful prognostically in AS.
After the initial study describing Zva, the follow-up retro-
spective study from the same group (16) showed that Zva
provided prognostic information. The accompanying edito-
rial by Baumgartner and Otto (17) pointed out that: 1) there
are significant “intrinsic limitations of Zva” and 2) there
were very major limitations of the study. These related to
cause(s) of death, disease course, medical therapy, and
patient management. In a recent editorial, Pibarot and
Dumesnil (18) showed that Zva was 4.5 in all 3 subgroups
of patients. In other words, Zva is a prognosticator. Studies
have not presented positive and negative predictive values of
Zva nor has it been shown to be a validated prospective
predictor, at least not one that is clinically useful.
H. In AS, higher prevalence of aortic arch plaques in AS
and complex plaques were independently associated with
cerebral infarction. Transesophageal echocardiography
was performed in 116 patients with severe AS who were
scheduled to undergo AVR (19). Compared with age- and
sex-matched control subjects, patients with AS had a greater
prevalence of aortic arch plaques (74% vs. 41%; p 0.0001)
and complex plaques (30% vs. 10%; p  0.004). Complex
plaques were defined as large plaques (4 mm), ulcerated
plaques, or mobile plaques. Multivariate analyses after
adjusting for traditional atherosclerotic risk factors and
coronary artery disease showed that complex arch plaques
were independently associated with cerebral infarction (odds
ratio [OR]: 8.46; 95% CI: 2.38 to 30.12; p  0.001).
Comment: These findings may have implications for
stroke in those who have percutaneous valve implantation
(see the following).
Aortic Regurgitation
A. Incremental prognostic value of B-type natriuretic
peptide in asymptomatic patients with severe aortic
regurgitation and normal LVEF >55%. Of 294 consec-
utive patients who were studied, the first 160 served as the
derivation cohort for the level of B-type natriuretic peptide
(BNP) to categorize patients at higher risk of symptoms of
HF, LV systolic dysfunction, or death at follow-up (20).
The cutoff value of BNP for the best predictive value was
130 pg/ml. By multivariate analysis, BNP 130 pg/ml
was the strongest independent predictor with an OR of 6.9
(95% CI: 2.52 to 17.57; p  0.0001) (Table 2). In the
validation cohort, a BNP 130 pg/ml had an OR of 6.7
(95% CI: 2.9 to 16.9; p  0.0001), which was of incremen-
tal prognostic value to standard prognosticators.
Bicuspid Aortic Valve
A. Low incidence of aortic complications in those with a
bicuspid aortic valve. From the population-based setting
in Olmsted County, Minnesota, a cohort of 416 (35  21
years of age) had a bicuspid aortic valve (BAV). At
follow-up to 25 years (mean, 16 7 years), aortic dissection
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without baseline aneurysms, an aneurysm developed in 49
(0.849%). The need for aortic surgeries developed in 25%
(95% CI: 17.2% to 32.8%), mostly for aortic aneurysms.
B. Surgery for BAV (valve alone) and BAV with proactive
aortic repair (valve-aortic repair). From January 1993 to
June 2003, 1,989, patients underwent surgery for BAV. Of
1,810 with suitable echocardiograms, 1,449 (80%) had BAV
surgery alone and 361 (20%) had BAV surgery plus ascend-
ing aortic repair. The hospital mortality rate in the 2 groups
was 1.2% and 1.1%, respectively (p 0.9) (22). At 10 years,
n the matched cohort, the risk-adjusted survival rate in the
subgroups was 86% versus 85%, respectively (p  0.7).
Patients undergoing valve alone surgery had aortic diame-
ters4.6 cm; at an aortic diameter size4.5 cm, only 0.2%
of events occurred. The ascending aorta was also analyzed in
an additional way as the ratio of aortic cross-sectional area
to height. Svensson et al. (22) concluded that “aortic size
4.5 cm or aortic cross sectional area/height ratio greater
than 8 to 10 should be considered triggers for concurrent
aortic repair.”
Comment: At the present time, the most commonly used
parameter is aortic diameter size.
Mitral Stenosis
A. New risk score predicts functional result up to 20 years
after catheter balloon commisurotomy. Of 1,024 consec-
utive patients undergoing catheter balloon commisurotomy
for severe mitral stenosis, 912 (89%) had good immediate
results grade (mitral valve area 1.5 cm2 without mitral
regurgitation grade2/4). At 20 years, their overall survival
rate was 74.9  2.3%, the survival rate without cardiovas-
cular death was 84.7  2%, the survival rate without
intervention was 37.8  2.3%, and 33.3  2.2% had good
functional results (23). The 912 patients were randomly
divided into groups of 609 and 303 patients to develop and
validate a scoring system to predict late function results. A
13-point scoring system that was developed defined 3 risk
groups with scores of 0 to 2, 3 to 5, and 6 to 13, with good
functional results at 20 years in 55.1%, 29.1%, and 10.5%,
respectively.
Comment: This is an excellent and innovative study from
Multivariate Analysis to Predict theCombined Endpoint in AR: Derivation SetTable 2 Multivariate Analysis to Pr dict theCombined Endpoint in AR: Derivation Set
Endpoint OR (95% CI) p Value
BNP 130 pg/ml 6.9 (2.52–17.57) 0.0001
ESD/BSA 24 mm/m2 3.4 (1.88–11.9) 0.01
EROA 50 mm2 4.3 (2.4–12.4) 0.001
EDD 35 mm/m2 2.1 (0.88–13.7) 0.09
Reprinted, with permission, from Pizarro et al. (20).
AR  aortic regurgitation; BNP  B-type natriuretic peptide; EDD  end diastolic dimension;
ROA  effective regurgitant orifice area; ESD/BSA  end systolic diameter/body surface area;
I  confidence interval; OR  odds ratio.an experienced and skilled center. fMitral Regurgitation
A. Excellent long-term results of Carpentier’s technique
of mitral valve repair for Barlow’s disease is reproducible.
Within the group of “degenerative” mitral regurgitation
(MR), 2 distinctive entities have been described, Barlow’s
disease and fibroelastic deficiency. From 2001 to 2007, a
total of 453 patients underwent mitral valve (MV) surgery,
200 of whom had Barlow’s disease (24). Repair was feasible
in 182 (91%); the reminder had MVR. The hospital
mortality rate was 1.5%. At 8 years, the survival rate was
88.6  3.1%, the cardiac death rate was 6.4  2.3%, the
reintervention rate was 4.7 1.7%, and the rate of recurrent
MR was 9.8  3.1%. These results were similar to those
reported earlier in the pioneering phase of the surgery.
Comment: It would have been very valuable to also know
from this very experienced and skilled center the incidence
and outcomes of MV repair (MVrep) in the 253 patients
who had fibroelastic deficiency.
B. Does MVrep improve survival in patients undergoing
CABG? Data from the STICH (Surgical Treatment for
Ischemic Heart Failure) Hypothesis 1 trial. The STICH
trial is a multicenter, nonblinded study that randomized
1,212 patients at 99 medical centers in 22 countries over 4.8
years, which on average is 2.6 patients/center/year (25).
Patients had to have an LVEF 0.35, which was evaluated
at the recruiting sites and coronary artery disease amenable
to CABG; the decision to perform MV surgery was deter-
mined at each individual site. Data on the assessment of
LVEF, severity of MR, and the medical therapy that
patients received were not provided. Of 91 patients with
moderate-severe MR randomized to CABG, 49 under-
went MVrep and 42 did not After adjustment for baseline
prognostic variables, the HR for death in those with
CABG  mitral surgery versus CABG alone was 0.41
(95% CI: 0.22 to 0.77; p  0.006).
Comment: This study has a large number of variations.
There was a very small number of patients in those
randomized to MVrep versus no MVrep (49 vs. 42). There
ere no data on myocardial hibernation in these 2 sub-
roups. A previous study documented that functional MR
mproved after CABG in those who had5 LV myocardial
egments that were hibernating (26).
. Assessing the severity of MR. 1. Visual assessment.
he core laboratory of echocardiographic studies in STICH
as at the Mayo Clinic (27). Their analysis showed that: 1)
VEF actually was 0.35 in 18.5% of patients; and 2) MR
everity by visual assessment was associated with a wide
ange of effective regurgitant orifice areas (Fig. 3).
. Direct visualization of regurgitant orifice. Direct as-
essment of regurgitant orifice area was determined by
ardiovascular magnetic resonance (28). The severity of MR
as based on the severity of regurgitant fraction. The
egurgitant orifice area correlated with the regurgitant
raction (r  0.80, p  0.001).
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try of the regurgitant orifice area geometry; in MR of
different etiologies, it ranged from 1.24 to 3.91. The authors
carefully pointed out that current cardiac magnetic reso-
nance technology as used in their study cannot measure the
true surface of the MR orifice, which may have a complex
3-dimensional surface but can only be visualized as a
2-dimensional surface.
Comment: The accompanying editorial by Paul Grayburn
(29) is superior.
3. Cardiac magnetic resonance documents LV remodel-
ing in degenerative MR in spherical in mid- to apical
areas. Ninety-four patients (54  11 years of age; 38%
female) underwent cine cardiac magnetic resonance imaging
and 3-dimensional analysis (30). The echocardiographic
studies in MR have used the standard LV end- systolic
dimension measured at the tips of the papillary muscles.
This study documents that the spherical changes in the
mid- to apical areas of the LV results in the LVESD
measurements estimated by echocardiography are not accu-
rate for determining LV end-systolic volumes at rest and
also after corrective surgery.
D. Functional MR due to atrial fibrillation. Fifty-three
of 828 patients (6.4%) who had first atrial fibrillation
ablation had moderate MR (31). A random cohort of 53
from the remaining 660 had mild or less MR and were
selected as a reference cohort. Patients with MR were older
(61.6  8.4 vs. 55.4  12.4 years of age, p  0.003) and
more often had persistent atrial fibrillation (62% vs. 23%,
p  0.0001). MR patients also had larger left atrial size (32
cm3/m2 vs. 26 cm3/m2, p 0.008) and annular size (3.49 vs.
.23 cm, p  0.001). LVEF, LV end-diastolic and end-
Figure 3 ERO Severity of MR in the STICH Trial
Findings of effective regurgitant orifice (ERO) and visual assessment of severity
of mitral regurgitation (MR) at the core laboratory in the STICH trial. There is
considerable range of EROs for all grades of MR. MR none to trivial (blue),
mild (yellow), moderate (green), moderate to severe (magenta), severe (red).
Reprinted, with permission, from Oh et al. (27).ystolic dimensions, and LV wall thickness were similar. At oollow-up, a mean of 277 days after ablation, patients in
ontinuous sinus rhythm had less MR (24% vs. 82%, p 
.005) and a significant decrease in annular dimension.
. Is cardiac resynchronization therapy beneficial in
atients with HF, moderate-severe functional MR, and
igh surgical risk? . . . Yes, in one-half of those who
urvive to 6 months. Ninety-eight consecutive patients
ith HF and moderate-severe MR had cardiac resynchro-
ization therapy, and 13 died within 6 months (32). Of the
emaining 85 patients, MR improved in 42 (49%) by 1
rades (labeled MR improvers) and the rest were labeled
onimprovers. Survival in improvers versus nonimprovers at
year was 97% and 88%, respectively, and at 2 years, it was
2% and 67%, respectively (p  0.001). At baseline, of 33
with a nonischemic cause of HF, 22 (67%) were improvers
and of 52 with ischemic HF, only 20 (38%) were improvers
(p  0.015). MR improvement was an independent prog-
nostic factor for survival (HR: 0.35; 95 CI: 0.13 to 0.94;
p  0.043).
Tricuspid Regurgitation
A. State-of-the-art paper: the growing clinical impor-
tance of secondary tricuspid regurgitation (33).
B. Clinically silent tricuspid regurgitation at the time of
MVrep for MV prolapse has a benign natural history up to
>5 years. From 1995 through 2006, 699 patients had
isolated MVrep for severe MR due to MV prolapse. Their
ges were 60.4 13.7 years, and 66% were male. Associated
ricuspid regurgitation (TR) that was clinically silent was
ot surgically treated (34). TR was diagnosed and quanti-
ated by echocardiography/Doppler performed preopera-
ively, intraoperatively, and post-operatively. TR grade was
in 33.3%, grade 2 in 50.2%, and grades 3 to 4 in 16.5%
n  115). Atrial fibrillation was present in 17.5%. Dilation
f the right ventricle was present in 4.4% and of the right
trium in 29%. There were 4 early deaths (0.6%), 2 of them
0.3%) within 30 days of surgery. The survival rate at 5 and
0 years was 93.9% and 76.1%, respectively. TR grade
ecreased significantly (p  0.001) at time of hospital
ischarge and also on follow-up up to 3 years. Of 115
atients with TR grades 3 to 4, only 1 required reoperation
or TR at 4.5 years.
omment: This study emphasizes the importance of
killed auscultation and clinical examination.
. Tricuspid valve repair of mild-moderate functional
R in patients undergoing MVR for rheumatic MV
isease. Of 236 patients with mild-moderate TR from
997 to 2009, 123 underwent tricuspid valve repair and 113
id not (35). Follow-up was up to 12 years (median, 48.7
onths; interquartile range, 20.2 to 89.5 months). After
djustments, both groups had a similar risk of deaths,
ricuspid reoperation, and HF. Those with moderate-severe
R postoperative had similar survival but worse combined
utcomes of death, reoperation, and HF.
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March 26, 2013:1290–301 Year in Valvular Heart DiseaseD. Endocardial pacemaker/defibrillator lead placement
after insertion of bioprosthetic tricuspid valve. In 58
atients, endocardial lead placement was successful and did
ot lead to a significant difference in TR (36).
nfective Endocarditis
“Endocarditis is always bad news.”
—Ann F. Bolger (37)
A. Early prediction of adverse outcomes in left-sided
endocarditis. Data are from 5 tertiary hospitals in Spain
nd 317 consecutive patients within 3 days of hospital
dmission for infective endocarditis (38). It helped to derive
independent risk factors (Staphylococcus aureus organism,
HF, paravavular extension of infection) for death or urgent
surgery; it was called a derivation study. They then tested
these variables in internal (same hospitals) or external (at
another tertiary hospital) and validation studies. The dis-
criminatory power of the model expressed as area under the
receiver-operating curve was similar against internal valida-
tion (0.67 vs. 0.68, p  0.79) and external validation (0.67
vs. 0.74, p  0.09). There was a progressive, significant
attern of increasing event rates as the risk stratification
core increased in both validation cohorts (p  0.001 by the
hi-square test for trend) (Table 3).
omment: This is an excellent and valuable study. The
ccompanying editorial by Bolger (37) is superior; it em-
hasizes succinctly the important issues, which included:
) the need for early diagnosis including transoesophageal
chocardiography within 12 to 24 h of hospital admission;
) identifying patients at high risk very early; and
) management of certain patients at referral centers that
ave a specific interest or experience in medical and surgical
reatment of endocarditis. I would add that procedures of
nproven value in infective endocarditis, such as whole-
ody imaging, are inappropriate.
. Importance of valve surgery for patients in HF. A
otal of 4,075 patients with infective endocarditis and
Rate of Events in Infective Endocarditis Dependingon the Number a d Typ of Variables Pr se tTable 3 Rate o Events in Infective Endocarditis Dependingon the Number and Type of Variables Present
Internal Validation
Sample, %
External Validation
Sample, %
0 variables 31 30
Perivalvular complication 65 58
Staphylococcus aureus 64 41
Heart failure 56 78
1 variable overall 60 62
Staphylococcus aureus 
perivalvular complication
80 25
Heart failure  perivalvular
complication
71 95
Staphylococcus aureus 
heart failure
100 88
2 variables overall 82 85
3 variables 100 100(Reprinted, with permission, from Lo´pez et al. (38).nown HF were enrolled in the International Collaboration
n Endocarditis Prospective Cohort Study; 1,359 (33%) had
F and 906 were classified as having New York Heart
ssociation functional class III or IV symptoms (39). Of
,359 patients, 839 (61.7%) had valve surgery during the
ndex hospitalization. The in-hospital mortality rate was
9.7%. The mortality rate in those who had surgery plus
edical therapy and in those receiving only medical therapy
uring hospitalization was 20.6% and 44.8%, respectively
p  0.001), and at 1 year, it was 29.1% and 58.4%,
espectively (p  0.001). Valvular surgery during hospital-
zation was associated with lower mortality.
. Randomized trial: early surgery reduces the incidence
f death plus embolic event at 6 weeks and 6 months in
hose with large vegetations and severe valve disease. Pa-
ients with left-sided infective endocarditis and severe valve
isease with vegetation diameter 10 mm who had the
iagnostic workup completed within 24 h of hospital
dmission were randomized to early surgery (n  37) or
onventional therapy (n  39) (40). Patients in the early
urgery group had surgery at a median time of 24 h
interquartile range, 7 h to 45 h). At 6 weeks, the incidence
f death plus embolic event at 6 weeks in the early surgery
roup versus the conventional therapy group was 3% versus
3% (p  0.01), and at 6 months, it was 3% versus 28%
p  0.003). It is important to note that of the 39 patients
ssigned to conventional therapy, 30 (77%) also had surgery
uring the initial hospitalization or during follow-up.
omment: This is an important and valuable randomized
rial. It showed that the outcome is better with medical
herapy plus early surgery than with medical therapy plus
ater surgery. In the early surgery group, the embolic rate
as 0.
. Early and late outcomes after surgery in native MV:
nfective endocarditis with cardiogenic/septic shock.
rom May 1991 to December 2009, data for 379 patients
ere collected from 8 institutions and separated into 3
roups: group 1, no shock, n  154; group 2, cardiogenic
hock, n  118; and group 3, septic shock, n  107 (41).
heir ages were 53  6.6, 55.4  8.9, and 61.0  11.3
ears, respectively. The overall 30-day mortality was 21.6%;
n the 3 subgroups, it was 14.6%, 19.5%, and 65.8%,
espectively (the p values for groups 2 and 3 vs. group 1 were
0.001). In the survivors, the 18-year survival rate was
5.2%, which was not significantly different among the 3
ubgroups.
ranscatheter Valve Therapy: Aortic
. Multisociety expert consensus documents.
. Transcatheter aortic valve replacement (42).
. Operator and institutional requirements for transcatheter
valve repair and replacement (43).
. Randomized trials: 2-year data. The PARTNER B
Placement of Aortic Transcatheter Valves) trial compared
3
D
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(Edwards Lifesciences, Irvine, California) via the trans-
femoral route with standard therapy in patients with severe
AS and considered not suitable for surgery. Standard
therapy included balloon aortic valvuloplasty in 85.3%. Data
on 2-year outcomes (44) are shown in Table 4. Survival in
those with low, mid, and high Society of Thoracic Surgeons
scores are shown in Figure 4. TVT compared with standard
therapy was associated with improved functional class (p 
0.001).
Comment: One-year data were published previously (45).
Areas of concern were described (46). The very major ones
had included: 1) the performance of balloon valvuloplasty in
85% of patients in the standard therapy group, which is
known to have a worse outcome and had been abandoned;
2) death of unknown cause as due to cardiovascular cause;
3) the likelihood that many patients did not have high
Society of Thoracic Surgeons scores, which the 2 year data
confirm; and 4) post-procedure, the high incidence of AR in
Data at 2 Years in the PARTNER B TrialTable 4 Data at 2 Years in the PARTNER B Trial
Standard Therapy
(n  179) TVT (n  179) p Value
All-cause mortality 68 43.3 0.001
Stroke 5.5 13.8 0.01
Repeat hospitalization 72.5 35 0.001
Cardiac death 62.4 31 0.001
Balloon aortic valvuloplasty 85.3 2.8 0.001
Aortic valve replacement 8.9 0.9 0.005
All values are percentages. Reprinted, with permission, from Makkar et al. (44).
TVT  transcatheter valve therapy.
Figure 4 PARTNER B Trial: 2-Year Mortality by Risk Scores
Time to event (all-cause mortality) by Kaplan-Meier analysis depending on the Soc
standard therapy (blue). The figure in the original publication was labeled on the y
permission, from Makkar et al. (44). CI  confidence interval; TAVR  transcathetthe standard therapy would adversely affect outcomes. The
negative impact of AR is now confirmed in the 2-year
results of the PARTNER A trial (47).
The PARTNER A trial compared TVT with the Sapien
valve (Edwards Lifesciences) via the transfemoral or
transapical route to surgical AVR in high-risk patients with
severe AS. The Society of Thoracic Surgeons score pre-
dicted that the mean risk of death at 30 days was 11.8 
.4%. Of 351 patients, 38 (10.8%) did not undergo surgery.
ata on 2-year outcomes (47) are shown in Table 5.
oderate or severe paravalvular regurgitation was more
ommon after TVT than after SAVR (at 2 years, 6.9% vs.
.9%; p  0.0001). At 2 years, the presence of paravalvular
egurgitation was unchanged in 46.2%, had improved in
1.5%, and was worse in 22.4%. The mortality rates in those
ith AR are shown in Figure 5. Any AR versus none was
ssociated with an increased late mortality rate (HR: 2.11;
Thoracic Surgery (STS) risk scores with transcatheter valve therapy (red) versus
s “survival,” and the legend correctly described as “mortality.” Reprinted, with
e replacement.
Data at 2 Years in the PARTNER A TrialTable 5 Data at 2 Years in the PARTNER A Trial
Surgical AVR
(n  351) TVT (n  348) p Value
Death
All-cause 35 33.9 0.78
Cardiovascular cause 20.5 21.4 0.8
Repeat hospitalization 21.7 24.7 0.41
Stroke or TIA (total) 6.5 11.2 0.05
Myocardial infarction 1.5 0 0.05
Major vascular complication 3.8 11.6 0.001
Major bleeding 29.5 19 0.002
All values are percentages. Reprinted, with permission, from Kodali et al. (47).
AVR  aortic valve replacement; TIA  transient ischemic attack; TVT  transcatheter valve
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ssociation functional class was similar in the 2 subgroups;
t was functional class III or IV in the TVT group in 16.1%
nd 14.8% in the SAVR group.
omment: One-year data was published previously (48).
reas of concern were described. It was emphasized that the
xpected outcomes in those in whom AR developed would be
orse (49). Many patients were not at high risk, and the 38
atients who did not have surgery may have affected the results.
. Cerebral embolic phenomena after aortic TVT.
. Using diffusion-weighted magnetic resonance imaging.
f 31 patients undergoing TVT with Core Valve, newly docu-
ented cerebral infarcts occurred in 24 (77%) and stroke in 2 (6%)
atients (50). Stroke was associated with a greater number and
olume of cerebral infarcts. Predictors of the number of new
Figure 5 PARTNER A Trial: Relationship of AR After Transcathe
All-cause mortality by Kaplan-Meier methods to severity of aortic regurgitation (AR)
to severe AR (red) (A, C) and with mild (red) and moderate-severe AR (green) (B,erebral infarcts were age (r  0.37, p  0.042), severity ofatheroma (of the aortic arch [r  0.91, p  0.001] and of the
descending aorta [r 0.69, p 0.001]), and catheterization time
r  0.45, p  0.002). There was no association between the
number of new cerebral infarcts and altered health status.
Comment: For the prevalence of aortic arch plaques and inci-
dence of cerebral infarction (19) (see study in the AS section).
Should all patients being considered for SAVR and for TVT
undergo pre-procedural transoesophageal echocardiography?
2. Using a transcranial Doppler study. High-intensity
transient signals were used as a surrogate for microemboli-
zation and were detected in all 83 patients during manipu-
lation of the calcified aortic valves while TVT valves were
being positioned and implanted (51). There were no signif-
icant differences between the transfemoral and transapical
Edwards Sapien valves or between the Edwards Sapien or
alve Therapy to All-Cause Mortality
as-treated population. None or trace AR (blue) is compared with mild
eprinted, with permission, from Kodali et al. (47). CI  confidence interval.ter V
in the
D). RMedtronic Core Valves. High-intensity transient signals
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There was 1 major procedural stroke that resulted in death,
1 minor procedural stroke that resulted in death, and 1
minor procedural stroke with full recovery at 3-month
follow-up in the Medtronic Core Valve group.
D. Acute kidney injury with aortic TVT increases
mortality. Periprocedural acute kidney injury occurred in
4 (14.6%) of 165 patients according to the Valve Academic
esearch Consortium definition (increase in serum creati-
ine 0.3 mg/dl or 1.5  baseline at 72 h) and in 19
atients (11.5%) according to RIFLE criteria (modified
isk, injury, failure, loss, and end-stage kidney disease)
decrease of 25% in estimated glomerular filtration rate at
8 h) (52). These patients were from a single center that
articipated in the PARTNER trials. Those in whom acute
idney injury was more likely included in men (63% vs.
8%, p  0.03) and patients receiving blood transfusion
63% vs. 39%, p  0.04). On multivariate analysis, only
lood transfusion emerged as a predictor of acute kidney
njury (OR: 3.74, 95% CI: 1.36 to 10.3). Patients in whom
cute kidney injury developed had a higher in-hospital
ortality rate (21% vs. 4%, p 0.007) and 30-day mortality
ate (29% vs. 7%, p  0.004).
. Aortic TVT versus aortic TVT  percutaneous coronary
ntervention. A retrospective review of 254 patients in the
ercutaneous coronary intervention (PCI) database with
evere AS who underwent PCI between 1998 and 2000 and
sing propensity-matching 508 patients without AS who
nderwent PCI (53). The 30-day mortality rate was 4.7%
ersus 4.3% (p  0.2).
In patients who underwent PCI, the 30-day mortality rate
as higher in those with an LVEF of 0.30 than those with
n LVEF 0.30 (5.4% vs. 1.2%, p  0.001). Similarly,
atients with severe AS had a higher 30-daymortality rate after
CI in those with a Society of Thoracic Surgeon score of10
han those with a score 10 (10.4% vs. 0%; p  0.001).
retrospective evaluation of 125 patients who had aortic
VT at a single institution (54). Seventy patients had
solated aortic TVT of whom 56% had previous PCI or
ABG (group 1) and 55 had aortic TVT plus pre-procedural
CI of all significantly obstructed major epicardial coronary
rteries (group 2). All patients with aortic TVT had the
edtronic Core Valve. The 30-day mortality rate in the 2
roups was 6% and 2%, respectively (p  0.27). The 30-day
ncidence of stroke, major bleeding, major vascular complica-
ion, and Valve Academic Research Consortium–defined
ombined safety endpoints was 11% and 13% (p  0.74).
dverse events at 6 months were comparable (p  NS).
. Moderate or severe versus mild or no MR is associated
ith higher early mortality and an improvement in MR
t 1 year in about half of the patients. In 2 Canadian
enters undergoing aortic TVT, the role of associated MR was
valuated (55). The 30-day mortality rate in 319 patients with
ild or no MR, 89 with moderate MR, and 43 with severe
R was 8%, 14%, and 16%, respectively (p  0.07). The
-year survival rate in the 3 groups was 79.0%, 76.2%, and 64.5%, respectively, and at 2 years was 66.2%, 67.0%, and
8.5%, respectively. At 1 year, MR severity was improved in
5% of patients with moderate or severe MR.
ranscatheter Valve Therapy: Mitral
. Percutaneous valve-in-ring procedure for MVR. A
easibility study was performed in 5 sheep of percutaneous
V implantation in those with pre-existing MV annulo-
lasty (56). The valve-in-ring procedure was performed via
he atrial septum using Melody valves (Medtronic). The
alve-in-ring procedure was technically successful and re-
uired 1 h of procedure time. Angiography showed no
ignificant MR in 4, moderate central MR in the animal
ith a 28-mm annuloplasty, no LV outflow tract obstruc-
ion, and no AR.
rosthetic Heart Valve
. Long-term outcome after AVR in the elderly. Late
urvival was evaluated in 2,890 consecutive patients who had
VR from 1993 through 2007 (57). Thirty-one percent of
atients were 70 to 74 years of age, 32% were 75 to 79 years
f age, 25% were 80 to 84 years of age, and 12% were 85
ears of age and older. The hospital mortality rate was 4%.
edian times in the intensive care unit and of hospitaliza-
ion were 37 h and 8 days, respectively. The 5-, 10-, and
5-year survival rates versus expected survival rate in the
opulation were 68%, 34%, and 8% versus 70%, 42%, and
0%, respectively (p  0.001). A scoring system was
eveloped based on a multivariate HR for late death (Table 6).
hose in the lowest risk score group of 1 to 5 had the best
ong-term survival and those in the highest score group of
12 had the lowest survival. Of the patients, 92% had a
iological valve and 8% had a mechanical valve (Fig. 6). In
he highest score group, survival with a biological valve was
etter than with a mechanical valve (p  0.004).
omment: This is an excellent and valuable study.
. Aortic valve surgery, 2004 through 2009: UK and
reland national database. A total of 41,227 patients
nderwent AV surgery from April 2004 through March
009 with an in-hospital mortality rate of 4.11% (58). From
004 through 2005 to 2008 through 2009, there were
ncreases in surgical volume from 7,396 to 9,333 as well as
ignificant increases (p  0.0005) in mean age (68.8 to 70.2
ears), proportion of patients with AS (62.4% to 65.1%),
ctogenarians (13.6% to 18.4%), high-risk patients (24.6%
o 27.7%), and those receiving biological valves (65.4% to
7.8%). There were decreases in permanent cerebrovascular
ccident (1.2% to 1%) and in total mortality (4.4% to 3.7%).
he survival rate at 2.5 years was 89%.
. LV diastolic dysfunction is an important substrate for
nitiation of postoperative atrial fibrillation after cardiac
urgery. New atrial fibrillation within 30 days of surgery
eveloped in 135 of 351 (38.5%) patients (59). Patients with
ostoperative atrial fibrillation were older (72.5 10.3 years vs.
3.1 14.1 years; p 0.001). The incidence of postoperative
p
t
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
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single-valve procedure was 32.5% and 33.6%, respectively (p
0.85). Compared with isolated CABG, those undergoing
CABG  valve and multivalvar procedures, the increases in
ostoperative atrial fibrillation were 55.3% and 80%, respec-
ively, with p values of 0.001 and 0.03, respectively. By
ultivariate analysis, after adjusting for clinical and surgical
isk factors, independent predictors of postoperative atrial
brillation were older age (OR: 1.05, p 0.001), higher body
ass index (OR: 1.06, p  0.03), and abnormal LV diastolic
Multivariate Hazard Ratios for Late Death and RElderly P ients Undergoing Aortic Valve ReplacTable 6 Multivariate Hazard Ratios for LateElderly Patients Undergoing Aortic
Variable Estimate Mult
Age, yrs
75–79 0.23
80–84 0.62
85 1.05
LVEF 60% 0.16
Hypertension 0.14
Diabetes mellitus 0.36
Renal failure 0.73
Stroke 0.37
Myocardial infarction 0.25
Previous CABG 0.37
NYHA functional class III or IV 0.15
Immunosuppression 0.43
Pacemaker 0.36
Reprinted, with permission, from Ashikhmina et al. (57).
CABG coronary artery bypass graft; CI confidence interval; HR
Association.
Figure 6 Long-Term Survival After AVR
in Patients 75 Years of Age and Older
Stratification of the study group patients by risk score showing a lower long-
term survival rate after aortic valve replacement (AVR) in those with higher-risk
scores. Scores 1 to 5 (red), 6 to 8 (yellow), 9 to 11 (green) and 12 (blue).
Reprinted, with permission, from Ashikhmina et al. (57).unction grade 1 (OR: 5.12, p  0.006), grade 2 (OR: 9.87, p
0.001), and grade 3 (OR: 28.52, p  0.001).
D. Structural valve deterioration. Type 2 DM is associated
with faster SVD of a bioprosthetic valve. A prospective
12-center Italian study enrolled 6,184 patients (71.3  5.4
years of age, 60.1% male) from November 1988 through
December 2009; 1,731 (27.9%) had type 2 DM. Propensity
score matching yielded 1,113 patients in the DM and also in
the non-DM groups, 64.2% of DM patients were matched
(60). Hospital mortality was greater in the DM group (7.8%
vs. 2.9%). The 7-year incidence of SVD was also greater in
the DM group (26.8% vs. 4.6%, p  0.001). In a multivar-
iate Cox model, DM was the strongest predictor of SVD
(HR: 2.39; 95% CI: 2.28 to 3.5); other predictors were age
younger than 65 years, chronic renal failure, and increased
total cholesterol and triglycerides.
Comment: AS-DM patients have an increased incidence
of LV diastolic dysfunction (see earlier). Those with LV
diastolic dysfunction have a higher incidence of atrial
fibrillation after cardiac surgery (see earlier).
Modes of failure in explanted Mitroflow A12 pericardial
valves (Sorin Group Inc., Vancouver, Canada). Between
2001 and 2007, 12 valves were explanted (61); 7 (58%) were
due to SVD. These were characterized by para-stent post-
cusp tears (42%) and moderate to severe calcification (50%).
Most valves showed cusp thickening and collagen disruption
at the stent post and pannus. SVD “was observed in 100%
of the Mitroflow pericardial valves that had been in place for
more than 2 years” (61).
Valve Prosthesis–Patient Mismatch
A. A meta-analysis. This meta-analysis included 34 studies
comprising 27,186 patients. Moderate-severe valve prosthesis–
patient mismatch (VP-PM) was associated with a statistically
cores of Allt (N  2,890)h and Risk Scores of All
Replacement (N  2,890)
e HR 95% CI p Value Risk Score
1.10–1.45 0.002 2
1.61–2.16 0.001 5
2.41–3.41 0.001 8
1.05–1.31 0.004 1
1.02–1.29 0.02 1
1.27–1.62 0.001 1
1.70–2.51 0.001 5
1.20–1.74 0.001 2
1.12–1.47 0.001 2
1.23–1.69 0.001 3
1.01–1.34 0.04 1
1.25–1.88 0.001 3
1.11–1.84 0.006 3
ratio; LVEF left ventricular ejection fraction; NYHANew York Heartisk SemenDeat
Valve
ivariat
1.26
1.87
2.87
1.17
1.15
1.44
2.07
1.45
1.28
1.44
1.17
1.53
1.43significant increase in all-cause mortality. Data from only 7 of
1300 Rahimtoola JACC Vol. 61, No. 12, 2013
Year in Valvular Heart Disease March 26, 2013:1290–30134 studies showed that bothmoderate and severe VP-PMwere
associated with statistically significant increases in all-cause and
also cardiac-related mortality (62).
Comment: An accompanying editorial by Daneshvar and
myself (63) concluded that one would want a convincing
and critical analysis proving that severe VP-PM is the cause
of, or an independent predictor of, cardiac-cause mortality.
This study does not provide it. The authors responded to
our editorial in a letter to the editor (64) to which we
responded (65).
B. An invited state-of-the-art paper. Daneshvar and my-
self (66) stated that the concept/phenomenon of VP-PM,
described in 1978, has stood the test of time. Our literature
survey identified 47 relevant studies, all of which were
included. From 1978 through 2011, VP-PM has received a
great deal of attention, but studies have come to varying
conclusions. This is largely because of the determination of
prosthetic heart valve area (called the effective orifice area
index) by projection rather than by actual measurement,
variable criteria to assess severity of effective orifice area
index, and the timing of determination of effective orifice
area index. All prosthetic heart valves have some degree of
VP-PM, which must be placed in a proper clinical perspec-
tive. This can be done by determining its effects on function
and outcomes. For mortality, one needs to focus especially
on the severe/critical degree of VP-PM and determine that
the cause of death was due to VP-PM. For the period
beyond 2011, a road map is suggested that will have
uniformity of assessment of VP-PM and a focus on the
important goals of VP-PM. A commentary (67) was pro-
vided by Pibarot and Dumesnil.
Comment: The commentary reflects the author’s views and
data, which are problematic. Many areas of concern were
covered in a state-of-the-art paper (66). The additional
issues are the following. 1) In the Veterans Administration
randomized trial of prosthetic heart valves (68), the causes
of deaths were adjudicated. Only 40% of all deaths after
SAVR were related to the prosthesis, and 60% of them were
caused by bleeding. Thus, one has to be very careful about
stating VP-PM as the cause of death by evaluating total
cardiac mortality. 2) All prosthetic heart valves have an
effective orifice area index that is smaller than normal, and
thus all such patients have a VP-PM, which is very unlikely
to become “obsolete,” as is suggested in the commentary. 3)
Predicting the valve effective orifice area index rather than
measuring it at the correct time, determining the severity of
VP-PM by criteria that are problematic, and combining
moderate and severe (moderate-severe) VP-PM ensures
that such data may become irrelevant.
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himtoola, University of Southern California, 1200 North State
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